First Personalized CRISPR Therapy Treats Rare Liver Disorder in Infant
| Key Aspect | Details |
|---|---|
| Patient | KJ Muldoon, a 9-month-old infant from the United States |
| Condition | CPS1 deficiency - a rare, life-threatening liver disorder |
| Treatment | Personalized CRISPR-based gene editing, specifically base editing |
| Delivery Method | Lipid nanoparticles targeting the liver |
| Institutions Involved | Children's Hospital of Philadelphia (CHOP) and Penn Medicine |
| Doctors Leading Research | Dr. Kiran Musunuru and Dr. Rebecca Ahrens-Nicklas |
| Outcome | Significant improvement in KJ's health with no severe side effects reported |
| Background on CPS1 | Inherited urea cycle disorder; liver fails to convert toxic ammonia into urea |
| Standard Treatments | Protein-restricted diets, medications, and liver transplants |
| CRISPR Technique Used | Base editing - changes a single letter of DNA without cutting the strand |
| Development Timeline | Therapy developed, tested, and administered within six months of diagnosis |
| Significance | First-of-its-kind therapy tailored to an individual patient's mutation |
| Potential Impact | Framework for treating other rare disorders; minimizes reliance on lifelong medications or surgeries |